Zhang Yu-jie, Ma Chang-hua, Lu Wan-liang, Zhang Xuan, Wang Xiao-liang, Sun Jian-ning, Zhang Qiang
School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100083, China.
Acta Pharmacol Sin. 2005 Nov;26(11):1402-8. doi: 10.1111/j.1745-7254.2005.00174.x.
To investigate the enhancing effects of chitosan with or without enhancers on nasal recombinant hirudin-2 (rHV2) delivery in vitro and in vivo, and to evaluate the ciliotoxicity of these formulations.
The permeation-enhancing effect of various chitosan formulations was estimated by using the permeation coefficient of fluorescein isothiocyanate recombinant hirudin-2 (FITC-rHV2) across the excited rabbit nasal epithelium in vitro. The effect was further evaluated by measuring the blood concentration level after nasal absorption of FITC-rHV2 in rats. The mucosal ciliotoxicity of different formulations was evaluated with an in situ toad palate model.
Chitosan at a concentration of 0.5% with or without various enhancers significantly increased the permeability coefficient (P) and relative bioavailability (Fr) of FITC-rHV2 compared with the blank control. The addition of 1% sodium dodecylsulfate, 5% Brij35, 5% Tween 80, 1.5% menthol, 1% glycyrrhizic acid monoammonium salt (GAM) or 4% Azone into the 0.5% chitosan solution resulted in a further increase in absorption (P<0.05) compared with 0.5% chitosan alone. But co-administration of chitosan with 5% hydroxyl-propyl-beta-cyclodextrin (HP-beta-CD), 5% lecithin or 0.1% ethylenediamine tetraacetic acid (EDTA) was not more effective than using the 0.5% chitosan solution alone. Chitosan alone and with 5% HP-beta-CD, 0.1% EDTA, 1% GAM or 5% Tween 80 was relatively less ciliotoxic.
Chitosan with or without some enhancers was able to effectively promote the nasal absorption of recombinant hirudin, while not resulting in severe mucosal ciliotoxicity. A chitosan formulation system would be a useful approach for the nasal delivery of recombinant hirudin.
研究壳聚糖在有或无增强剂情况下对重组水蛭素 -2(rHV2)鼻腔给药的体外和体内增强作用,并评估这些制剂的纤毛毒性。
通过异硫氰酸荧光素重组水蛭素 -2(FITC - rHV2)体外透过离体兔鼻黏膜上皮的渗透系数,评估各种壳聚糖制剂的促渗效果。通过测定大鼠鼻腔吸收FITC - rHV2后的血药浓度水平进一步评估该效果。用原位蟾蜍腭模型评估不同制剂的黏膜纤毛毒性。
与空白对照相比,含或不含各种增强剂的0.5%壳聚糖显著提高了FITC - rHV2的渗透系数(P)和相对生物利用度(Fr)。在0.5%壳聚糖溶液中添加1%十二烷基硫酸钠、5%聚氧乙烯月桂醚、5%吐温80、1.5%薄荷醇、1%甘草酸单铵盐(GAM)或4%氮酮,与单独使用0.5%壳聚糖相比,吸收进一步增加(P<0.05)。但壳聚糖与5%羟丙基 -β-环糊精(HP -β- CD)、5%卵磷脂或0.1%乙二胺四乙酸(EDTA)联合使用并不比单独使用0.5%壳聚糖溶液更有效。单独的壳聚糖以及与5% HP -β- CD、0.1% EDTA、1% GAM或5%吐温80联合使用时纤毛毒性相对较小。
含或不含某些增强剂的壳聚糖能够有效促进重组水蛭素的鼻腔吸收,同时不会导致严重的黏膜纤毛毒性。壳聚糖制剂系统将是重组水蛭素鼻腔给药的一种有效方法。